Search
Brentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalThis demonstrates meaningful progress in treatment for patients affected by this disease.[L1739]
Products: ADCETRIS 50 MG (POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION), POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIALRasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalThe cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_.
Categories: Detoxifying Agents for Antineoplastic TreatmentProducts: FASTURTEC POWDER FOR SOLUTION FOR INFUSION 1.5 mg/vialAlbutrepenonacog alfa
go.drugbank.com/drugs/DB13884ApprovedAlbutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). It was developed by CSL Behring Canada, Inc and approved by Health Canada ...
Products: IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIAL, IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnThe FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Powder for Injection 500mg, DORIBAX 500 MG (Doripenem) for InjectionPegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigational[A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer … [L9974] NIOPEG (pegfilgrastim), a biosimilar of NEULASTA®, was approved by Health Canada in April 2024 for the prevention of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive
Products: Fulphila 6 mg/ 0.6 mL Solution for Injection, Pelgraz Solution for Injection in pre-filled syringe 6mg/0.6mLClofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to ...
Products: EVOLTRA 1 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION, NUCLOFAR Clofarabine 1mg/mL Concentrate for Solution for InfusionArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigationalArtesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria. … [L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
Products: ARTESUNATE FOR INJECTION, ARTESUN POWDER FOR INJECTION 60 MGTeriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigationalTeriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Eu...
Products: FORTEO 250 UG SOLUTION FOR INJECTION, KAULIV 20 micrograms/80 microliters solution for injectionMagnesium
go.drugbank.com/drugs/DB14513ApprovedInvestigational[A32810] Further, the mineral helps regulate blood pressure and is necessary for RNA, DNA and protein synthesis among several other functions.
Mixtures: For-2, Doctor's Choice Brand for MenProducts: MAGNESIOCARD FOR 10MMOL OR, BIOLECTRA MAGN 243 FOR ORAPaliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalPaliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. … It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor AntagonistsProducts: INVEGA Sustenna Prolonged Release Suspension for IM Injection 25mg/0.25 ml, INVEGA Sustenna Prolonged Release Suspension for IM Injection 50mg/0.5 ml